Back to Journals » Neuropsychiatric Disease and Treatment » Volume 7 » Issue 1

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands

Authors Hoogveldt B, Rive, Severens J, Maman K, Guilhaume C

Published 15 June 2011 Volume 2011:7(1) Pages 313—317

DOI https://doi.org/10.2147/NDT.S19239

Review by Single-blind

Peer reviewer comments 2


Bart Hoogveldt1, Benoît Rive2, Johan Severens3, Khaled Maman4, Chantal Guilhaume5
1
Field Product Management, Lundbeck BV, Amsterdam, The Netherlands; 2Global Outcomes Research, Lundbeck SAS, Issy-les-Moulineaux, France; 3Institute of Health Policy and Management, Erasmus University Rotterdam, The Netherlands; 4Creativ Research SAS, Paris, France; 5Global Evidence and Value Development, Sanofi-Aventis, Paris, France

Objective: The purpose of this study was to estimate the cost-effectiveness of memantine relative to standard care in patients with moderate-to-severe Alzheimer's disease in the Netherlands.
Methods: A country-adapted five-year Markov model simulated disease progression through a series of states, defined by dependency and disease severity. Transition probabilities were derived from trials, with utility and epidemiological data obtained from a longitudinal Dutch cohort. Cost-effectiveness was described in terms of quality-adjusted life years and time spent in a nondependent state or in a moderate severity state.
Results: Memantine monotherapy versus standard care led to 0.058 quality-adjusted life years gained (1.207 versus 1.265), longer time in a nondependent state (from 1.602 to 1.751 years) and in a moderate state (from 2.051 to 2.141 years), and no additional costs (€113,927 versus €110,097). Robustness of results was confirmed through sensitivity analyses.
Conclusion: Memantine is dominant compared with standard care in the Netherlands. Results are consistent with similar economic evaluations in other countries.

Keywords:
memantine, Alzheimer's disease, cost-effectiveness analysis, Netherlands, cholinesterase inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]